Enavogliflozin Improves Non-invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials.

Envlo (enavogliflozin) - Daewoong Pharma, GC Biopharma, M8 Pharma

Enavogliflozin Improves Non-invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials. (PubMed, Diabetes Obes Metab) - Jun 16, 2026 - No abstract available
Journal • Retrospective data • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

http://www.ncbi.nlm.nih.gov/pubmed/42297759

Areum Lee; Chang Hee Jung; Hae Jin Kim; Han Sol Lee; In Kyung Jeong; Min Kyoung Jang; So Hun Kim; Su-Jin Jeoung; Suk Chon; Sung Hoon Yu; Yong-Ho Lee

Jun 16, 2026